infectious-diseases-2018-posters-abstracts

31 / 35

Infectious Diseases 2018 Journal of Prevention and Infection Control
ISSN: 2471-9668 Page 70
June 07-08, 2018
London, UK
8th Edition of International Conference on
Infectious Diseases
Introduction: Leishmaniasis is a vector-borne disease that is
caused by obligate intra-macrophage protozoa of the Leishmania
species. Leishmaniasis can cause different clinical syndromes,
including cutaneous leishmaniasis (CL), in which the patient
generally presents with one or several ulcer(s) or nodule(s) on the
skin, resulting from the infection of phagocytic cells located in the
dermis. It often results into severe scar tissue in the skin. Most of
the twelve million people infected with Leishmania worldwide are
CL cases, a 1.5 million new cases occur annually.
Objective: WHO has a program to develop new treatments for
cutaneous leishmaniasis. This study establishes a proof-of-
concept that a tattoo device can target intra-dermal drug delivery
against cutaneous leishmaniasis (CL).
Methods: The selected drug is oleylphosphocholine (OlPC)
formulated as liposomes, particles known to be prone to
macrophage ingestion. First is shown that treatment of cultured
Leishmania-infected macrophages with OlPC-liposomes results
in a direct dose-dependent killing of intracellular parasites. Based
on this, in vivo efficacy is demonstrated using a 10-day tattooing-
mediated treatment inmice infectedwith L.major andL.mexicana.
In both models this regimen results in rapid clinical recovery with
complete regression of skin lesions by day 28. Parasite counts
and histopathology examination confirm high treatment efficacy
at the parasitic level. Low amount of drug required for tattooing
combined with fast clinical recovery may have a positive impact
on CL patient management.
Results: This first example of tattoo-mediated drug delivery
could open to new therapeutic interventions in the treatment of
skin diseases. This study demonstrates that the use of a tattoo
instrument for drug delivery is possible in the treatment of
cutaneous leishmaniasis, and that this method can successfully
eliminate intracellular parasites at the site of infection. After
showing that the selected drug oleylphosphocholine (OlPC)
formulated as liposomes could efficiently reach intracellular
parasites when in contact with infected macrophages, the
activity of the drug was compared in vivo in mouse models of
old (L. major) and new world (L. mexicana) leishmaniasis. Three
routes of administrations of the same drug formulation were
investigated: systemic (IP) administration, topical administration
as a drop, and administration via the tattoo instrument. Evaluation
parameters included clinical (lesion sizes) and parasitological
parameters (burdens) using quantitative and qualitativemethods.
In all experiments, the tattooing delivery procedure was the most
efficacious at both the clinical and parasitological levels.
Drug delivery by tattooing to treat cutaneous leishmaniasis
Stef Stienstra
Royal Dutch Armed Forces, Netherlands
J Prev Infect Cntrol 2018, Volume 4
DOI: 10.21767/2471-8084-C1-003